Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

NCT07215637 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Metastatic Solid Tumors

Interventions

DRUG: CKD-512
COMBINATION_PRODUCT: Pembrolizumab

Sponsor

Chong Kun Dang Pharmaceutical